Naringenin pretreatment attenuates hepatic ischemia-reperfusion injury by activating the PI3K-Akt signaling pathway

Figure 3 Naringenin pretreatment reduces inflammatory response and oxidative stress in hepatic ischemia-reperfusion injury. A: Immunofluorescence staining images of CD11b+ cells in liver tissues; B: Quantitative analysis of CD11b+ positive cells (n = 3); C: MRNA expression levels of pro-inflammatory cytokines interleukin-1β (n = 3); D: MRNA expression levels of pro-inflammatory cytokines interleukin-6 (n = 3); E: MRNA expression levels of pro-inflammatory cytokines tumor necrosis factor-α (n = 3); F: Levels of malondialdehyde in liver tissue (n = 6); G: Levels of superoxide dismutase in liver tissue (n = 6); H: Levels of reduced glutathione in liver tissue (n = 6). Scale bar: 100 μm. ^aP < 0.05 vs the Sham group, ^bP < 0.05 vs the ischemia-reperfusion injury group. NAR: Naringenin; IRI: Ischemia-reperfusion injury; IL: Interleukin; TNF-α: Tumor necrosis factor-α; MDA: Malondialdehyde; SOD: Superoxide dismutase; GSH: Reduced glutathione.